AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$CMMB

Cohen Neil Harris sold $7K of CMMB

Cohen Neil Harris sold 2,304 shares of Chemomab Therapeutics Ltd. (CMMB) at an average of $2.83 ($2.80–$2.85) across 2 trades over 2026-08-27 to 2026-08-28.

Original reporting
SEC EDGAR · Cohen Neil Harris
Published Sep 1, 2026, 2:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 2:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CMMB
Neutral
high confidence
Mentioned
$CMMB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMMBNeutralLow
01

Why it matters

The disclosed sale is unlikely to move the stock but adds to the insider activity record.

02

Market read

Low relevance; the transaction size is trivial and does not affect valuation.

03

What to watch

Potential upcoming corporate actions or financing that prompted the sale.

Relevance 3/10Novelty 4/10Timing: filed Sep 1, 2026

Background

Form 4 filings disclose insider transactions; directors' sales are monitored for signals.

Company-level read

Ticker impact

$CMMBNeutralHigh confidence
Context

Director Cohen Neil Harris sold 2,304 shares for $6,516, reducing his stake to 33,000 shares.

Expected impact

No material move expected.

Evidence & confidence

The transaction size is small ($6.5k) and represents a modest reduction in holdings; market typically ignores such low‑value sales.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor future filings.

Key entities

  • Company
    Chemomab Therapeutics Ltd.

    Biotech issuer of the Form 4.

  • Person
    Cohen Neil Harris

    Director of Chemomab Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CMMB insider trading history →

Related articles

JUL 8
$CMMBMedAI 8/10

Chemomab Therapeutics, Scipher Medicine Announce Merger Agreement, Stock Down In Pre-Market

Chemomab Therapeutics (CMMB) and Scipher Medicine agreed to merge, forming a Nasdaq-listed company trading as SCIP. The combined firm will advance nebokitug, an anti-CCL24 antibody, into a Phase 2 rheumatoid arthritis trial. Chemomab holders expected to own ~32% and Scipher ~68%, with contingent value rights. About $30M new funding; cash expected to fund through H2 2028. Deal expected to close Q4 2026; CMMB down to $2.39 pre-market.

rttnews.com6 min
JUL 8
$CMMBHighAI 9/10

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine (Nasdaq-bound) announced a definitive merger in a stock deal, with the combined company to trade on Nasdaq as Scipher Medicine Corporation under ticker “SCIP”. The focus will be advancing nebokitug, an anti-CCL24 antibody, into a Phase 2 RA trial, with topline results expected in H1 2028. A $30M private placement is planned, valuing the deal at $150M pre-placement, and cash is expected to fund operations into H2 2028.

manilatimes.net3 min
JUL 8
$CMMBMedAI 9/10

Chemomab Therapeutics Ltd.: Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine (Nasdaq-bound) announced a definitive merger to combine in a stock deal, with the combined company to trade on Nasdaq as Scipher Medicine Corporation under ticker SCIP. The focus is advancing nebokitug, an anti-CCL24 antibody, into a Phase 2 RA trial using Scipher’s PrismRA test. A $30M private placement supports operations into H2 2028; Phase 2 readout expected H1 2028. Valuation cited at $150M pre-merger.

finanznachrichten.de6 min